Embryonic stem cell factor FOXD3 (Genesis) defects in gastrointestinal stromal tumors.
Humans
Animals
Mice
Gastrointestinal Stromal Tumors
/ genetics
Zebrafish
/ genetics
Stem Cell Factor
/ genetics
Comparative Genomic Hybridization
Proto-Oncogene Proteins c-kit
/ genetics
Receptor, Platelet-Derived Growth Factor alpha
/ genetics
Transcription Factors
/ genetics
Embryonic Stem Cells
/ chemistry
Mutation
Gastrointestinal Neoplasms
/ genetics
Forkhead Transcription Factors
/ genetics
Carney triad
Carney–Stratakis syndrome
FOXD3
GIST
interstitial cells of Cajal
Journal
Endocrine-related cancer
ISSN: 1479-6821
Titre abrégé: Endocr Relat Cancer
Pays: England
ID NLM: 9436481
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
received:
13
03
2023
accepted:
02
08
2023
pmc-release:
01
10
2024
medline:
12
9
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms, believed to originate from the interstitial cells of Cajal (ICC), often caused by overexpression of tyrosine kinase receptors (TKR) KIT or PDGFRA. Here, we present evidence that the embryonic stem cell factor FOXD3, first identified as 'Genesis' and involved in both gastrointestinal and neural crest cell development, is implicated in GIST pathogenesis; its involvement is investigated both in vitro and in zebrafish and a mouse model of FOXD3 deficiency. Samples from a total of 58 patients with wild-type GISTs were used for molecular analyses, including Sanger sequencing, comparative genomic hybridization, and methylation analysis. Immunohistochemistry and western blot evaluation were used to assess FOXD3 expression. Additionally, we conducted in vitro functional studies in tissue samples and in transfected cells to confirm the pathogenicity of the identified genetic variants. Germline partially inactivating FOXD3 sequence variants (p.R54H and p.Ala88_Gly91del) were found in patients with isolated GISTs. Chromosome 1p loss was the most frequent chromosomal abnormality identified in tumors. In vitro experiments demonstrate the impairment of FOXD3 in the presence of those variants. Animal studies showed disruption of the GI neural network and changes in the number and distribution in the ICC. FOXD3 suppresses KIT expression in human cells; its inactivation led to an increase in ICC in zebrafish, as well as mice, providing evidence for a functional link between FOXD3 defects and KIT overexpression leading to GIST formation.
Identifiants
pubmed: 37578265
doi: 10.1530/ERC-23-0067
pii: e230067
pmc: PMC10564589
mid: NIHMS1926804
doi:
pii:
Substances chimiques
Stem Cell Factor
0
Proto-Oncogene Proteins c-kit
EC 2.7.10.1
Receptor, Platelet-Derived Growth Factor alpha
EC 2.7.10.1
Transcription Factors
0
FOXD3 protein, human
0
Forkhead Transcription Factors
0
Banques de données
figshare
['10.6084/m9.figshare.16439055.v1']
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA HD008920
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA101956
Pays : United States
Références
J Physiol. 2008 Feb 15;586(4):1185-94
pubmed: 18096603
J Clin Endocrinol Metab. 2009 Oct;94(10):3656-62
pubmed: 19723753
Development. 2008 May;135(9):1615-24
pubmed: 18367558
J Biol Chem. 1999 Jan 15;274(3):1573-80
pubmed: 9880535
Arch Pathol Lab Med. 2006 Oct;130(10):1466-78
pubmed: 17090188
Am J Pathol. 1998 May;152(5):1259-69
pubmed: 9588894
Genes Chromosomes Cancer. 2022 Jul;61(7):412-419
pubmed: 35170141
Biochim Biophys Acta Mol Cell Res. 2019 Dec;1866(12):118531
pubmed: 31415841
J Neurosci Methods. 2020 Jul 15;341:108720
pubmed: 32416472
Front Oncol. 2022 Aug 01;12:884814
pubmed: 35978808
Am J Hum Genet. 2008 Apr;82(4):903-15
pubmed: 18355774
Dev Biol. 2006 Apr 1;292(1):174-88
pubmed: 16499899
Cancer Genet Cytogenet. 2001 May;127(1):30-3
pubmed: 11408061
Dev Dyn. 2009 Apr;238(4):875-86
pubmed: 19301400
Biotechniques. 2003 Feb;34(2):374-8
pubmed: 12613259
Cancer Res. 2000 Jul 15;60(14):3899-903
pubmed: 10919666
N Engl J Med. 2007 Sep 6;357(10):1054-6
pubmed: 17804857
Endocr Relat Cancer. 2018 Feb;25(2):R49-R58
pubmed: 29170162
Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15785-90
pubmed: 16243968
Carcinogenesis. 2020 Sep 24;41(9):1253-1262
pubmed: 31784734
JAMA Oncol. 2016 Jul 1;2(7):922-8
pubmed: 27011036
Exp Biol Med (Maywood). 2018 Feb;243(4):327-333
pubmed: 29307282
J Clin Endocrinol Metab. 2011 Jan;96(1):E135-40
pubmed: 20881257
Cancer Cell Int. 2019 Feb 28;19:44
pubmed: 30858761
J Clin Endocrinol Metab. 2007 Aug;92(8):2938-43
pubmed: 17535989
Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3663-7
pubmed: 11891324
Dev Cell. 2018 Dec 3;47(5):608-628.e6
pubmed: 30513303
Genes Dev. 2002 Oct 15;16(20):2650-61
pubmed: 12381664
Exp Mol Pathol. 2015 Oct;99(2):374-82
pubmed: 26112097